New method to accelerate vaccine and drug development for norovirus
en-GBde-DEes-ESfr-FR

New method to accelerate vaccine and drug development for norovirus


Researchers from The University of Osaka have developed a simple and efficient system for understanding the functions of specific norovirus genes, providing new avenues for developing antivirals and vaccines

Osaka, Japan – Norovirus is the leading cause of gastroenteritis and is responsible for hundreds of thousands of deaths every year. However, research progress into antiviral treatments and vaccines has been hindered by the absence of a robust ‘reverse genetics’ system.

Now, a team at The University of Osaka has successfully overcome this long-standing barrier to norovirus research, developing a simple and efficient research system for human norovirus.

Reverse genetics systems allow the functions of genes to be determined by changing an individual gene and observing the result, creating what is known as a ‘recombinant’ virus. They are powerful tools for studying how viruses replicate and cause disease, and aid in the development of novel antiviral therapies and vaccines. The team at The University of Osaka applied virological techniques to a zebrafish model to create a novel reverse genetics system capable of generating infectious human noroviruses.

The system they developed involves the direct injection of norovirus cDNA clones into zebrafish embryos, which is a very simple and efficient method to generate infectious noroviruses. The team demonstrated the utility of this system by generating genetically manipulated noroviruses, possessing specific mutations or tagged with ‘reporter genes’.

Reporter genes are genetic modifications, such as chemiluminescent molecules, that can tag the virus and report on its activity and location within a host cell, enabling visualization of the virus in action. This ability to manipulate the virus enables the mechanisms of viral replication and pathogenesis to be investigated.

“This will also allow the development of novel vaccines with controlled antigenicity and pathogenicity,” explains senior author Takeshi Kobayashi.

This system fills a critical gap in human norovirus research. The ability to support antiviral screening and accelerate vaccine development could make it a transformative tool for the field. As this approach becomes more widely used, it will lay the groundwork for more effective public health strategies and a markedly reduced global burden of norovirus infection.
###
The article, “Recovery of infectious recombinant human norovirus using zebrafish embryos”, was published in PNAS at DOI: https://doi.org/10.1073/pnas.2526726122
Title: Recovery of Infectious Recombinant Human Norovirus Using Zebrafish
Embryos
Journal: Proceedings of the National Academy of Sciences of the United States of America
Authors: Tomohiro Kotaki, Yuki Akieda, Zelin Chen, Megumi Onishi, Sayuri Komatsu, Daisuke Motooka, Hiroko Omori, Shigeyuki Tamiya, Yuta Kanai, Shohei Minami, Takahiro Kawagishi, Naomi Sakon, Shintaro Sato, Tohru Ishitani, and Takeshi Kobayashi
DOI: 10.1073/pnas.2526726122
Funded by:
Japan Agency for Medical Research and Development
Japan Science and Technology Agency
SECOM Science and Technology Foundation
Article publication date: 04-DEC-2025
Related links:
Takeshi Kobayashi
https://www.biken.osaka-u.ac.jp/en/researchers/detail/21
Archivos adjuntos
  • Fig. 1 Outline of Recombinant Human Norovirus Generation Using Zebrafish Embryos©Original content, No restrictions., Takeshi Kobayashi (Created with Biorender.com)
Regions: Asia, Japan, North America, United States
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement